Details

Autor(en) / Beteiligte

• Wall, Michael
• Johnson, Chris A
• Cello, Kimberly E
• Zamba, K D
• McDermott, Michael P
• Keltner, John L

Titel

Visual Field Outcomes for the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT)

Ist Teil von

• Investigative ophthalmology & visual science, 2016-03, Vol.57 (3), p.805-812

Ort / Verlag

United States: The Association for Research in Vision and Ophthalmology

Erscheinungsjahr

2016

Quelle

MEDLINE

Beschreibungen/Notizen

• The Idiopathic Intracranial Hypertension Treatment Trial (IIHTT) showed that acetazolamide provided a modest, significant improvement in mean deviation (MD). Here, we further analyze visual field changes over the 6-month study period. Of 165 subjects with mild visual loss in the IIHTT, 125 had perimetry at baseline and 6 months. We evaluated pointwise linear regression of visual sensitivity versus time to classify test locations in the worst MD (study) eye as improving or not; pointwise changes from baseline to month 6 in decibels; and clinical consensus of change from baseline to 6 months. The average study eye had 36 of 52 test locations with improving sensitivity over 6 months using pointwise linear regression, but differences between the acetazolamide and placebo groups were not significant. Pointwise results mostly improved in both treatment groups with the magnitude of the mean change within groups greatest and statistically significant around the blind spot and the nasal area, especially in the acetazolamide group. The consensus classification of visual field change from baseline to 6 months in the study eye yielded percentages (acetazolamide, placebo) of 7.2% and 17.5% worse, 35.1% and 31.7% with no change, and 56.1% and 50.8% improved; group differences were not statistically significant. In the IIHTT, compared to the placebo group, the acetazolamide group had a significant pointwise improvement in visual field function, particularly in the nasal and pericecal areas; the latter is likely due to reduction in blind spot size related to improvement in papilledema. (ClinicalTrials.gov number, NCT01003639.).